VistaGen Therapeutics shares are trading higher after the company announced it will present fasedienol safety and exploratory efficacy data from its Phase 3 open-label social anxiety disorder study at the ASCP 2023 Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
VistaGen Therapeutics (VTGN) announced it will present fasedienol safety and exploratory efficacy data from its Phase 3 open-label social anxiety disorder study at the ASCP 2023 Annual Meeting, leading to higher trading of its shares.
May 31, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VistaGen Therapeutics shares are trading higher after announcing the presentation of fasedienol safety and efficacy data at the ASCP 2023 Annual Meeting.
The announcement of the presentation of fasedienol safety and efficacy data from VistaGen's Phase 3 study at the ASCP 2023 Annual Meeting is a positive development for the company. This news indicates progress in their clinical trials and may attract investor interest, leading to higher trading of VTGN shares in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100